



Overview

- Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive technique to ablate the prostate gland in prostate cancer patients.
- Our novel technology combines real-time MR imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise procedure tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. The potential of this technology is currently being demonstrated in clinical trials.
- Current therapies (radiation, surgery) may bring undesirable complications: incontinence, impotency and bowel problems. Profound's technology has the potential for fewer side effects.
- Technology developed at Sunnybrook Research Institute.
- Management team has extensive experience commercializing medical devices, specifically ablation technologies.
- Partnership with Philips announced in July 2015.

Heating Pattern



The Procedure



Prostate Cancer Treatment Options

Robotic Prostatectomy	IMRT (Intensity Modulated Radiation Therapy)	HIFU (High-Intensity Focused Ultrasound)	TULSA-PRO™
<ul style="list-style-type: none"> + Certainty of removing whole gland + Good outcome data - Invasive - Hospital stay - Post-surgical complications - High cost 	<ul style="list-style-type: none"> + Non-invasive - Collateral tissue damage - Multiple visits required - Recurrence - High cost 	<ul style="list-style-type: none"> + Minimally invasive - Transrectal delivery can result in complications - Collateral tissue damage - Prostate volume must be < 40 cc - Significant capital equipment cost 	<ul style="list-style-type: none"> + Minimally invasive + Quick treatment time + Highly accurate + Real-time MRI- guided + Prostate volume < 90 cc + Low complication rates - Requires compatible MRI equipment

Development & Commercialization

- The Phase 1 trial has demonstrated that MRI-guided TULSA provides accurate treatment planning, real-time thermal dosimetry and precise control of prostate ablation to within 1.3 mm, with a well-tolerated side-effect profile.

Outcomes:

- 30 patients treated with at least 12 month follow-up
- No intraoperative complications, no rectal injury or fistula
- Erectile dysfunction rate of 8% (IIEF item 2 ≥ 2)
- At 12 months, only 1 patient (3%) with Grade 1 urinary incontinence (no pads)
- Functional quality-of-life outcomes back to baseline levels
- Profound will launch a 100 patient, multi-jurisdictional Pivotal Trial in 2016. The device will be available in Canada and Europe in 2016 and, in the following year, the United States pending approval by the FDA.
- Patents: 5 issued in U.S. (System and Method), 7 pending in U.S., 6 pending Foreign Applications.
- Technology compatible with Philips and Siemens MRI platforms.
- Most hospitals equipped to perform prostatectomy will also have the equipment necessary to use Profound's technology.
- Potential other applications include: 1) Focal therapy: targeted ablation of cancerous tissue, leaving benign prostate tissue unharmed, and 2) The treatment of benign prostatic hyperplasia (BPH).

Selected Financial Data

Exchange & Ticker (commenced trading June 2015)		TSXV: PRN
Cash (@ September 30, 2015)		23.3MM
Debt:	FedDev	\$0.8MM
	HTX	\$1.5MM
	Knight	\$4.0MM
Common Shares (@ November 4, 2105) Basic; Fully Diluted		39.5MM;43.8MM
Significant Shareholders:	BDC	24.8%
	Genesys	23.1%
	Knight	7.7%